💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Velmanase Alfa

CHEMBL4298010 Phase 4 Одобрено Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
65.4 g/mol
LogP
—
Phase
4

Velmanase alfa is a recombinant human lysosomal alpha-mannosidase produced in Chinese hamster ovary cells for enzyme replacement therapy (ERT) in patients with alpha-mannosidosis, a rare lysosomal storage disease caused by deficiency of the alpha-mannosidase enzyme. It catalyzes the hydrolysis of mannose-containing oligosaccharides in lysosomes, preventing their pathological accumulation in cells. Regular intravenous infusions reduce mannose-rich oligosaccharide levels and improve clinical manifestations of the disease.

Молекулярная масса

65,4000 g/mol

TPSA

0,00 Ų

Механизм действия

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

SMILES

[Zn+2]

InChI

InChI=1S/Zn/q+2

Molecular Formula

Zn+2

HBD / HBA

- / -

Вращаемые Связи

0

Тяжёлые Атомы

1

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Velmanase alfa is a recombinant human lysosomal alpha-mannosidase produced in Chinese hamster ovary cells for enzyme replacement therapy (ERT) in patients with alpha-mannosidosis, a rare lysosomal storage disease caused by deficiency of the alpha-mannosidase enzyme. It catalyzes the hydrolysis of mannose-containing oligosaccharides in lysosomes, preventing their pathological accumulation in cells. Regular intravenous infusions reduce mannose-rich oligosaccharide levels and improve clinical manifestations of the disease.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Velmanase Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298010. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 32051. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.